Researchers have found a new way to reactivate fetal hemoglobin without the need for gene-editing therapy, according to a new study.

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, ...

The best healthcare stocks from Goldman Sachs' list that are also Quant Strong Buys have attractive valuations and forward ...

Discover how precision biotherapeutics can transform healthcare in India by personalizing treatments based on genetic and ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has not performed well for most of the year, and the company's latest quarterly update ...

This biotech has already made impressive contributions to medicine, and it could make more. But does that make it a buy?

In 2023, the U.S. Food and Drug Administration gave its approval to Casgevy, a commercial treatment that edits BCL11A genes ...

Priority voucher awardees and regulators could feel pressure to “meet the moment” as FDA watchers question the intent and ...

Keith Speights has positions in Amazon, Enbridge, and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...

Intellia Therapeutics NTLA is currently advancing two late-stage in vivo pipeline candidates – nex-z (or, NTLA-2001) for ...